CLSH CLS Holdings USA Inc

UN Unilever NV

AWK American Water Works Company Inc

AEG Aegon NV

SBUX Starbucks Corp

PFE Pfizer Inc

CRON Cronos Group Inc

CVSI CV Sciences Inc

Magenta Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is developing therapeutics to transform hematopoietic stem cell transplants for patients with immune and blood-based diseases. It maintains a platform with integrated and modular approach, which aims to reboot the blood and immune systems. The Company’s products include MGTA-145, MGTA-456, E478, and G100. The Company also developing a pipeline of small molecules; biologics, including antibody drug conjugates; and a cell therapy, which transplant options for many more patients with autoimmune diseases, blood cancers and genetic diseases. The Company’s C100 program targets HSCs, immune cells, and disease-causing cells, the C200 program targets HSCs and disease-causing cells and the C300 program targets only immune cells. This is achieved by tuning the antibodies to specific cellular markers or receptors that are expressed on the particular cell types.

New! Enhance the way you research investment opportunities with Social Signals, a one of a kind trading resource that pulls insights from Twitter. Watch the demo video

Rest of sector mixed after rally sparked by Altria investment in Cronos

Just days after Aurora Cannabis Inc. announced a supply deal with Mexico's Farmacias Magistrales SA, the Canadian cannabis company said it has entered a letter of intent to buy all of the company's outstanding shares in an all-stock deal.

Farmacias is Mexico's first and, for now, only federally licensed importer of raw materials containing THC, the psychoactive ingredient in cannabis, Aurora (ACB.T) (ACB.T) said in a statement. The company has the licenses and facilities to store and distribute medical products with more than 1% THC.

The deal "firmly establishes Aurora's first-mover advantage in one of the world's most populous countries, where more than 130 million people will have federally legal access to a range of Aurora's non-flower medical cannabis products containing THC," said the statement. Aurora also have operations in Colombia and Uruguay.

Farmacias has about 80,000 retail outlets for selling CBD products and 500 pharmacies and hospitals to sell THC products. Aurora will pay for the deal with stock based on a valuation of the proforma revenue distribution projections of Farmacias.

Farmacias will use imported THC and CBD concentrates to make cannabis oil products for the medical market. over time, it will expand to include products such as capsules, topical solutions and sprays and other delivery formats.

"Integrating Farmacias with our operations in Canada and Latin America will not only accelerate growth, it will build substantial long-term shareholder value," Aurora Chief Executive Terry Booth said in the statement.

Canadian-listed Aurora shares rose initially on the news, before reversing their gains to trade lower in early afternoon trade.

"We just got a new partner and now resources -- but beyond that the network and support [Altria] can offer -- being able to have that experience. It's an alignment and a partnership but it's not like the deal is over. We're all very, very excited about the beginning, and we can now go and do the things we want to do," he said in an interview.

Cormark Securities upgraded Cronos to buy from market perform on Monday and raised its stock price target to $17 from $10, or about 42% above its current trading level.

"We like the collaborative potential between the companies and see an immediate ability for CRON to benefit from Altria's existing pre-roll and device technology," analyst Jesse Pytlak wrote in a note.

Elsewhere in the sector, Canopy Growth Corp. (WEED.T) (WEED.T) shares were down about 0.6%, shedding early gains made after a bullish note from Benchmark. Analysts said they attended the company's analyst day last week and toured its Smiths Falls, Ontario facilities.

Hickey is expecting the 2018 Farm Bill to be approved by year-end, effectively legalizing CBD, or cannabidiol, the non-psychoactive ingredient in cannabis, which is used in a variety of medical products. The bill would remove industrial hemp from the government's list of controlled substances and is expected to open the market for rapid expansion.

"We believe WEED will invest meaningful capital into the U.S. after CBD legalization and leverage the Constellation Brands manufacturing profile to create CBD beverages; we expect a deployment strategy already firmly in place and will provide for near term growth," Hickey wrote.

Corona beer maker Constellation Brands (STZ) has invested $4 billion in Canopy Growth, a move expected to be followed by other big drinks companies.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.Please read Characteristics and Risks of Standard Options before investing in options.